Evicenter
P&T meetings

Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751
Manufacturer
AbbVie
Regulatory submission
NDA submitted September 2025
Last updated
217 sources

Economic information and modeling reportBudget impact model

Budget impact model discussion

3 evidence topics · 6 sources

Summary

The only budget impact analysis of tavapadon identified is the ICER potential budget impact analysis in the evidence report of 16 September 2026, which used a placeholder price of $15,000 per year because tavapadon had not yet received regulatory approval. AbbVie has published no price statement; a William Blair analyst, as reported by Benzinga on 28 September 2026, and ICER's public meeting slides of 1 October 2026 give a list price of $58,800 per year, and ICER's published budget impact results use the $15,000 placeholder. It sized an eligible United States population of 944,927 (436,786 first-line and 508,141 add-on to levodopa) and assumed that 20% would initiate treatment in each of five years. At the placeholder price, 46% of the first-line population and 59% of the add-on population could be treated before annual spending reached ICER's threshold of $821 million; at the add-on threshold prices ($4,501 to $7,123 per year), 100% could be treated. The analysis takes a health care cost perspective over five years without discounting and does not model a health plan membership. AbbVie's comments on the draft report stated that tavapadon is unlikely to displace levodopa as first-line therapy, which would reduce the first-line population the analysis includes, and that the budget-impact calculations are not presented in enough detail for independent verification. AbbVie expects a modest initial uptake because tavapadon will not be added to Medicare formularies immediately after approval. The actual budget impact will depend on the launch price and on how often tavapadon displaces generic dopamine agonists and levodopa, whose acquisition costs were $3,588 and $289 per year in the ICER models.

Manufacturer critique of the ICER economic analysis

“AbbVie unequivocally disagrees with ICER’s Draft Evidence Report conclusions regarding tavapadon.” (opens the source at this quote in a new tab)

“Evaluating tavapadon as a direct alternative to first-line oral levodopa may not reflect likely treatment patterns. As tavapadon enters the market, it is unlikely to displace levodopa as first-line therapy.” (opens the source at this quote in a new tab)

“AbbVie did not have full access to the economic model through ICER’s Model Transparency Program.” (opens the source at this quote in a new tab)

“Certain model outputs, cost inputs, terminology, and budget-impact calculations are not presented with sufficient detail to allow independent verification. This limits confidence that the reported results are fully reproducible and appropriate for use as a decision-making benchmark.” (opens the source at this quote in a new tab)

Manufacturer expectation of initial uptake

“To get to the nub of your question, we do see that the ramp will be modest at first, and I'll tell you why. It's not the profile of the medication. It's largely because based on the timing of the approval, we will not be immediately added into the Medicare formularies.” (opens the source at this quote in a new tab)